Management of small HER2-positive breast cancers (Q37815282)

23 August 2017

1 reference

title

Management of small HER2-positive breast cancers (English)

1 reference

23 August 2017

Susana Banerjee

1 reference

23 August 2017

Ian E Smith

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Lancet Oncology Commission

23 August 2017

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

1193-1199

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Decreased rates of advanced breast cancer due to mammography screening in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Late mortality from pT1N0M0 breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970119-4

7 January 2021

10.1016/S1470-2045(10)70119-4

Identifiers

DOI

1 reference

23 August 2017

1 reference